⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14737674 | 1.00 | — | — | |
| SCHEMBL1558368 | 0.82 | — | — | |
| SCHEMBL17818322 | 0.80 | — | — | |
| SCHEMBL328825 | 0.79 | PPM1D (0.32) | — | |
| SCHEMBL31421053 | 0.76 | — | — | |
| SCHEMBL22806968 | 0.75 | — | — | |
| SCHEMBL22819274 | 0.75 | — | — | |
| SCHEMBL30614209 | 0.74 | PPM1D (0.31) | — | |
| SCHEMBL27098133 | 0.74 | PPM1D (0.31) | — | |
| SCHEMBL17381861 | 0.74 | PPM1D (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084063-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| WO-2025042736-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-114874209-B | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| CN-114874209-A | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110461838-B | Oxadiazole transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2020072695-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2017040606-A1 | ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040606-A1 | ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| WO-2016115090-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-07-21 | — | — | WO | disclosed |
| WO-2015196071-A9 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |